{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:56:18Z","timestamp":1767707778402},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1007\/s11906-002-0063-9","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T20:11:30Z","timestamp":1180123890000},"page":"350-357","source":"Crossref","is-referenced-by-count":1,"title":["Managing the hypertensive patient with ischemic heart disease"],"prefix":"10.1007","volume":"4","author":[{"given":"Clive","family":"Rosendorff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"63_CR1","doi-asserted-by":"crossref","first-page":"7S","DOI":"10.1093\/ajh\/7.7.7S","volume":"7","author":"PW Wilson","year":"1994","unstructured":"Wilson PW: Established risk factors and coronary artery disease; the Framingham study. Am J Hypertens 1994, 7(Pt 2:7S-12S.","journal-title":"Am J Hypertens"},{"key":"63_CR2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1291\/hypres.18.181","volume":"18","author":"WB Kannel","year":"1995","unstructured":"Kannel WB: Framingham study insights into the hypertensive risk of cardiovascular disease. Hypertens Res 1995, 18:181\u2013196.","journal-title":"Hypertens Res"},{"key":"63_CR3","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/jama.1979.03300230018021","volume":"242","author":"Hypertension Detection and Follow-up Program Cooperative Group","year":"1979","unstructured":"Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979, 242:2562\u20132571.","journal-title":"JAMA"},{"key":"63_CR4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","volume":"291","author":"Research Council Working Party Medical","year":"1985","unstructured":"Medical Research Council Working Party: MRC trial of mild hypertension: principal results. Br Med J 1985, 291:97\u2013104.","journal-title":"Br Med J"},{"key":"63_CR5","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","unstructured":"SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program. JAMA 1991, 265:3255\u20133264.","journal-title":"JAMA"},{"key":"63_CR6","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/0140-6736(91)92589-T","volume":"338","author":"B Dahlof","year":"1991","unstructured":"Dahlof B, Lindholm LH, Hansson L, et al.: Morbidity and mortality in the Swedish Trial in Old Patients with hypertension (STOP-hypertension). Lancet 1991, 338:1281\u20131285.","journal-title":"Lancet"},{"key":"63_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.304.6824.405","volume":"304","author":"MRC Working Party","year":"1992","unstructured":"MRC Working Party: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992, 304:405\u2013412.","journal-title":"Br Med J"},{"key":"63_CR8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","volume":"350","author":"JA Staessen","year":"1997","unstructured":"Staessen JA, Fagard R, Lutgarde T, et al.: Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997, 350:757\u2013764.","journal-title":"Lancet"},{"key":"63_CR9","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/00004872-199816120-00016","volume":"16","author":"L Liu","year":"1998","unstructured":"Liu L, Wang JG, Gong L, et al.: Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998, 16:1823\u20131829.","journal-title":"J Hypertens"},{"key":"63_CR10","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.CIR.102.13.1503","volume":"102","author":"B Pitt","year":"2000","unstructured":"Pitt B, Byington RP, Furberg CD, et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000, 102:1503\u20131510.","journal-title":"Circulation"},{"key":"63_CR11","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.1996.03540100029024","volume":"276","author":"NO Borhani","year":"1996","unstructured":"Borhani NO, Mercuri M, Borhani PA, et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). JAMA 1996, 276:785\u2013791.","journal-title":"JAMA"},{"key":"63_CR12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","volume":"356","author":"L Hansson","year":"2000","unstructured":"Hansson L, Hedner T, Lund-Johansen P, et al.: Randomised trial of effects of calcium antagonists compared with diuretics and b-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359\u2013365.","journal-title":"Lancet"},{"key":"63_CR13","first-page":"372","volume":"356","author":"MJ Brown","year":"2000","unstructured":"Brown MJ, Palmer CR, Castaigne A, et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal on Hypertension Treatment (INSIGHT). Lancet 2000, 356:372.","journal-title":"Lancet"},{"key":"63_CR14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(00)03306-7","volume":"356","author":"M Pahor","year":"2000","unstructured":"Pahor M, Psaty BM, Alderman MH, et al.: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Lancet 2000, 356:1949\u20131954. The meta-analysis included nine trials of short- and long-acting, and dihydropyridine and nondihydropyridine calcium antagonists. Patients treated with calcium antagonists had a lower stroke risk, but a significantly increased risk of myocardial infarction, congestive heart failure, and combined major cardiovascular disease.","journal-title":"Lancet"},{"key":"63_CR15","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0140-6736(00)03307-9","volume":"356","author":"Blood Pressure Lowering Treatment Trials Collaboration","year":"2000","unstructured":"Blood Pressure Lowering Treatment Trials Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000, 356:1955\u20131964. This meta-analysis, published at the same time as Pahor et al. [14\u2022], provided strong support for the benefits of ACE inhibitors and calcium antagonists over placebo, and for intensive blood pressure lowering strategies over less intensive strategies. However, it found that when calcium antagonists were compared with diuretics and\/or \u00df -blockers, there was a significant lowering of stroke risk, but a nonsignificant increase in coronary heart disease and heart failure. ACE inhibitors were better than diuretics and\/or \u00df-blockers for heart failure prevention and better than calcium antagonists for both coronary heart disease and heart failure prevention.","journal-title":"Lancet"},{"key":"63_CR16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","volume":"358","author":"JA Staessen","year":"2001","unstructured":"Staessen JA, Wang J-G, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305\u20131315. Supports the idea that it does not matter which antihypertensive drug is used; the beneficial effects on cardiovascular outcomes is simply a function of the amount of blood pressure reduction. This conclusion fits uncomfortably with the findings from animal and human studies of the cardio- and vasculoprotective effects of ACE inhibitors, and to a lesser extent, calcium antagonists.","journal-title":"Lancet"},{"key":"63_CR17","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0735-1097(96)00251-3","volume":"28","author":"C Rosendorff","year":"1996","unstructured":"Rosendorff C: The renin-angiotensin system and vascular hypertrophy. J Am Coll Cardiol 1996, 28:803\u2013812.","journal-title":"J Am Coll Cardiol"},{"key":"63_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"The Heart Outcomes Prevention Evaluation Study Investigators","year":"2000","unstructured":"The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145\u2013153. A convincing demonstration of the protective effect of an ACE inhibitor for myocardial infarction and stroke in high-risk patients, almost half of whom were hypertensive","journal-title":"N Engl J Med"},{"key":"63_CR19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0735-1097(00)00736-1","volume":"36","author":"S MacMahon","year":"2000","unstructured":"MacMahon S, Sharpe N, Gamble G, et al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol 2000, 36:438\u2013443.","journal-title":"J Am Coll Cardiol"},{"key":"63_CR20","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1161\/01.CIR.102.15.1748","volume":"102","author":"K Teo","year":"2000","unstructured":"Teo K, Burton J, Buller C, et al.: Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin\/ enalapril Coronary Atheroscrerosis Trial (SCAT). Circulation 2000, 102:1748\u20131754.","journal-title":"Circulation"},{"key":"63_CR21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0002-9149(98)00780-2","volume":"83","author":"L Cashin-Hemphill","year":"1999","unstructured":"Cashin-Hemphill L, Holmvang G, Chan RC, et al.: Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Am J Cardiol 1999, 83:42\u201347.","journal-title":"Am J Cardiol"},{"key":"63_CR22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","volume":"353","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm L, Niskanen L, et al.: Effect of angiotensin- converting-enzyme inhibiton compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611\u2013616.","journal-title":"Lancet"},{"key":"63_CR23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/bmj.317.7160.713","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998, 317:713\u2013720.","journal-title":"Br Med J"},{"key":"63_CR24","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","volume":"354","author":"L Hansson","year":"1999","unstructured":"Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751\u20131756.","journal-title":"Lancet"},{"key":"63_CR25","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM199803053381003","volume":"338","author":"R Estacio","year":"1998","unstructured":"Estacio R, Jeffers B, Hiatt W, et al.: The effect of nisoldipine as compared with enapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998, 338:645\u2013652.","journal-title":"N Engl J Med"},{"key":"63_CR26","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahl\u00f6f","year":"2002","unstructured":"Dahl\u00f6f B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995\u20131003. The first, very large (over 9000 patients) study to evaluate the effects of an angiotensin receptor blocker on cardiovascular outcomes. Losartan was significantly better than atenolol in reducing total cardiovascular mortality and stroke, but there were no differences for myocardial infarction.","journal-title":"Lancet"},{"key":"63_CR27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(87)90231-5","volume":"1","author":"JM Cruickshank","year":"1987","unstructured":"Cruickshank JM, Thorp JM, Zacharias FJ: Benefits and potential harm of lowering high blood pressure. Lancet 1987, 1:581\u2013583.","journal-title":"Lancet"},{"key":"63_CR28","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","volume":"351","author":"L Hansson","year":"1998","unstructured":"Hansson L, Zanchetti A, Carruthers SG, et al.: Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755\u20131762. One purpose of this study was to examine the J-curve hypothesis. The group with the lowest achieved DBP had the lowest cardiovascular risk only in diabetic patients. Figure 3 in this study shows a graph of DBP versus cardiovascular mortality that looks very much like a J-shaped curve.","journal-title":"Lancet"},{"key":"63_CR29","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/01.CIR.100.4.354","volume":"100","author":"SS Franklin","year":"1999","unstructured":"Franklin SS, Khan SA, Wong ND, et al.: Is pulse pressure useful in predicting risk for coronary artery disease? The Framingham Heart Study. Circulation 1999, 100:354\u2013360.","journal-title":"Circulation"},{"key":"63_CR30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.7326\/0003-4819-136-6-200203190-00007","volume":"136","author":"F Boutitie","year":"2002","unstructured":"Boutitie F, Gueyffier F, Pocock S, et al.: J-shaped relationship between blood pressure and mortality in hypertensive patients: New insights from a meta-analysis of individualpatient data. Ann Intern Med 2002, 136:438\u2013448. A meta-analysis of seven randomized clinical trials of antihypertensive treatment showed that all-cause death rates were higher in patients with low (< 65 mm Hg) treated or untreated DBPs. This effect was greatest for noncardiovascular mortality, and less, but still present, for cardiovascular mortality. Unfortunately, we do not have data for coronary mortality.","journal-title":"Ann Intern Med"},{"key":"63_CR31","doi-asserted-by":"crossref","unstructured":"ACC\/AHA\/ACP-ASIM Guidelines for the management of patients with chronic stable angina. Circulation 1999, 99:2829\u20132848. The American College of Cardiology and American Heart Association Task Force on Practical Guidelines (in this case together with the American College of Physicians\/American Society of Internal Medicine) produce excellent recommendations for the management of common cardiologic problems. In these, the evidence for any particular procedure or treatment is ranked, mainly on the basis of the size and quality of the clinical trials. In addition, the confidence with which any procedure or treatment is suggested is given a range of Class I (useful and effective), Class IIa (conflicting evidence, but probably useful\/effective), Class IIb (usefulness\/efficacy is less well established by evidence\/opinion), and Class III (not useful or effective and may be harmful). I have included in the text only those recommendations with an a or b ranking for evidence, and a Class I ranking for confidence.","DOI":"10.1161\/01.CIR.99.21.2829"},{"key":"63_CR32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1093\/oxfordjournals.eurheartj.a014668","volume":"17","author":"HJ Dargie","year":"1996","unstructured":"Dargie HJ, Ford I, Fox KM: Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996, 17:104\u2013112.","journal-title":"Eur Heart J"},{"key":"63_CR33","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/01.CIR.95.10.2380","volume":"95","author":"C Held","year":"1997","unstructured":"Held C, Hjemdahl P, Rehnqvist N, et al.: Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis Study in Stockholm. Circulation 1997, 95:2380\u20132386.","journal-title":"Circulation"},{"key":"63_CR34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0735-1097(94)00345-Q","volume":"25","author":"T Arnim Von","year":"1995","unstructured":"Von Arnim T: Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol 1995, 25:231\u2013238.","journal-title":"J Am Coll Cardiol"},{"key":"63_CR35","doi-asserted-by":"crossref","unstructured":"ACC\/AHA Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. Circulation 2000, 102:1193\u20131209.","DOI":"10.1161\/01.CIR.102.10.1193"},{"key":"63_CR36","doi-asserted-by":"crossref","unstructured":"1999 Updated ACC\/AHA guidelines for the management of patients with acute myocardial infarction. Circulation 1999, 100:1016\u20131030.","DOI":"10.1161\/01.CIR.100.9.1016"},{"key":"63_CR37","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, Braunwald E, Moy\u2019e LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992, 327:669\u2013677.","journal-title":"N Engl J Med"},{"key":"63_CR38","first-page":"821","volume":"342","author":"The AIRE Investigators","year":"1993","unstructured":"The AIRE Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study. Lancet 1993, 342:821\u2013828.","journal-title":"Lancet"},{"key":"63_CR39","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","volume":"333","author":"L Kober","year":"1995","unstructured":"Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670\u20131676.","journal-title":"N Engl J Med"},{"key":"63_CR40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"The SOLVD Investigators","year":"1992","unstructured":"The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in symptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685\u2013691.","journal-title":"N Engl J Med"},{"key":"63_CR41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9149(90)90351-Z","volume":"66","author":"The Danish Study Group on Verapamil in Myocardial Infarction","year":"1990","unstructured":"The Danish Study Group on Verapamil in Myocardial Infarction: Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). Am J Cardiol 1990, 66:779\u2013785.","journal-title":"Am J Cardiol"},{"key":"63_CR42","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM198808183190701","volume":"319","author":"The Multicenter Diltiazem Postinfarction Trial Research Group","year":"1988","unstructured":"The Multicenter Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med 1988, 319:385\u2013392.","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-002-0063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-002-0063-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-002-0063-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:09:17Z","timestamp":1683853757000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-002-0063-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["63"],"URL":"https:\/\/doi.org\/10.1007\/s11906-002-0063-9","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}